2/9
02:43 pm
eols
Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating [Yahoo! Finance]
Low
Report
Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating [Yahoo! Finance]
2/4
10:15 am
eols
Evolus (NASDAQ:EOLS) was given a new $15.00 price target on by analysts at Mizuho.
Low
Report
Evolus (NASDAQ:EOLS) was given a new $15.00 price target on by analysts at Mizuho.
2/4
08:01 am
eols
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance]
Low
Report
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance]
2/4
07:56 am
eols
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance Canada]
Low
Report
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs [Yahoo! Finance Canada]
2/3
08:03 am
eols
Evolus (NASDAQ:EOLS) had its price target lowered by analysts at HC Wainwright from $20.00 to $13.00. They now have a "buy" rating on the stock.
Medium
Report
Evolus (NASDAQ:EOLS) had its price target lowered by analysts at HC Wainwright from $20.00 to $13.00. They now have a "buy" rating on the stock.
1/26
08:17 am
eols
How A New Price Target Is Shaping The Evolus (EOLS) Story [Yahoo! Finance]
Low
Report
How A New Price Target Is Shaping The Evolus (EOLS) Story [Yahoo! Finance]
1/22
08:06 am
eols
Evolus (NASDAQ:EOLS) had its price target lowered by analysts at BTIG Research from $18.00 to $13.00. They now have a "buy" rating on the stock.
Low
Report
Evolus (NASDAQ:EOLS) had its price target lowered by analysts at BTIG Research from $18.00 to $13.00. They now have a "buy" rating on the stock.
1/13
09:02 am
eols
Evolus (NASDAQ:EOLS) was given a new $17.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Evolus (NASDAQ:EOLS) was given a new $17.00 price target on by analysts at Stifel Nicolaus.
1/9
07:03 pm
eols
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue [Yahoo! Finance]
Low
Report
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue [Yahoo! Finance]
1/9
12:46 pm
eols
Evolus (NASDAQ:EOLS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Evolus (NASDAQ:EOLS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
1/9
09:01 am
eols
Evolus sees Q4 net revenue between $88.6M and $90.6M [Seeking Alpha]
Low
Report
Evolus sees Q4 net revenue between $88.6M and $90.6M [Seeking Alpha]
1/9
08:30 am
eols
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
Medium
Report
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue
12/24
08:02 am
eols
Evolus (NASDAQ:EOLS) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
Medium
Report
Evolus (NASDAQ:EOLS) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
12/19
07:08 pm
eols
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 [Yahoo! Finance]
Low
Report
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 [Yahoo! Finance]
12/1
09:02 pm
eols
Evolus (NASDAQ:EOLS) was given a new $19.00 price target on by analysts at Mizuho.
Medium
Report
Evolus (NASDAQ:EOLS) was given a new $19.00 price target on by analysts at Mizuho.
11/27
08:01 am
eols
Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability [Yahoo! Finance]
Low
Report
Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability [Yahoo! Finance]
11/19
02:55 pm
eols
The Dr. Randi Show Podcast, Sponsored by NewBeauty, Ranks in the Top 10% Globally for Conversations in Aesthetics, Beauty, Wellness & Medicine [Yahoo! Finance]
Low
Report
The Dr. Randi Show Podcast, Sponsored by NewBeauty, Ranks in the Top 10% Globally for Conversations in Aesthetics, Beauty, Wellness & Medicine [Yahoo! Finance]
11/14
04:05 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)